Scientific article
Open access

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Published inBlood advances, vol. 6, no. 17, p. 5171-5183
Publication date2022-09-13

Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers in 15 countries. Sequential patients were included. We identified 444 patients, with median follow-up 9.7 years (0-47.8). Forty-nine (11.1%) had a history of thrombosis at diagnosis, 49 new thrombotic events were recorded (1.16% patient per year [pt/y]), perihepatic vein thromboses were most frequent (47.6% venous events), and logistic regression identified JAK2V617F mutation (P = .016) and hyperviscosity symptoms (visual disturbances, dizziness, vertigo, headache) as risk factors (P = .040). New hemorrhagic events occurred in 44 patients (9.9%, 1.04% pt/y). Disease transformation occurred in 48 patients (10.9%, 1.13% pt/y), usually to myelofibrosis (7.5%) with splenomegaly as a novel risk factor for transformation in essential thrombocythemia (ET) (P= .000) in logistical regression. Eight deaths (1.8%) were recorded, 3 after allogeneic stem cell transplantation. Concerning conventional risk scores: International Prognostic Score for Essential Thrombocythemia-Thrombosis and new International Prognostic Score for Essential Thrombocythemia-Thrombosis differentiated ET patients in terms of thrombotic risk. Both scores identified high-risk patients with the same median thrombosis-free survival of 28.5 years. No contemporary scores were able to predict survival for young ET or polycythemia vera patients. Our data represents the largest real-world study of MPN patients age < 25 years at diagnosis. Rates of thrombotic events and transformation were higher than expected compared with the previous literature. Our study provides new and reliable information as a basis for prospective studies, trials, and development of harmonized international guidelines for the specific management of young patients with MPN.

  • Adult
  • Child
  • Humans
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / epidemiology
  • Polycythemia Vera / complications
  • Primary Myelofibrosis / genetics
  • Prospective Studies
  • Thrombocythemia, Essential
  • Thrombosis / etiology
  • Young Adult
Citation (ISO format)
SOBAS, Marta et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. In: Blood advances, 2022, vol. 6, n° 17, p. 5171–5183. doi: 10.1182/bloodadvances.2022007201
Main files (1)
Article (Published version)
Secondary files (1)
ISSN of the journal2473-9529

Technical informations

Creation02/26/2024 5:24:08 PM
First validation04/09/2024 3:45:37 PM
Update time04/09/2024 3:45:37 PM
Status update04/09/2024 3:45:37 PM
Last indexation05/06/2024 6:21:27 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack